Ginkgo Bioworks Holdings (DNA) Change in Working Capital (2022 - 2023)
Ginkgo Bioworks Holdings posted quarterly Change in Working Capital of $4.7 million for Q2 2023, up 76.52% year-on-year from $2.7 million in Q2 2022, and down 44.5% on a QoQ basis from $8.5 million in Q1 2023.
Ginkgo Bioworks Holdings (DNA) has 2 years of Change in Working Capital data on file, last reported at $4.7 million in Q2 2023.
- For the quarter ending Q2 2023, Change in Working Capital rose 76.52% year-over-year to $4.7 million; the trailing twelve-month figure through Jun 2023 stood at $18.6 million (changed N/A YoY), and the FY2022 full-year result was $10.8 million, changed N/A from the prior year.
- Change in Working Capital for Q2 2023 stood at $4.7 million, down from $8.5 million in the prior quarter.
- Across five years, Change in Working Capital topped out at $8.5 million in Q1 2023 and bottomed at $2.7 million in Q1 2022.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Working Capital (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | - |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | - |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | - |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | - |
| 10 | Ginkgo Bioworks Holdings | 542.03 Mn | 542.03 Mn | 16.38 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 4.73 Mn |
| Jun 30, 2023 | 4.73 Mn |
| Mar 31, 2023 | 8.52 Mn |
| Mar 31, 2023 | 8.52 Mn |
| Jun 30, 2022 | 2.68 Mn |
| Jun 30, 2022 | 2.68 Mn |
| Mar 31, 2022 | 2.65 Mn |
| Mar 31, 2022 | 2.65 Mn |